The current diagnostic methods for prostate cancer are not always as reliable or accurate as they could be, leading to mis- or over-diagnosis, and thus the treatment of patients who will not benefit from it. In this interesting interview, Mark Emberton, MD, FRCS, of University College London, London, UK, discusses the key challenge in this area: effective risk stratification. Prof. Emberton highlights the need in this area, touching upon trials of promising drugs and comparing them to similar therapeutics that have been studied in breast cancer. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.
Challenges for prostate cancer: overdiagnosis and unnecessary treatment
